FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Ingle

Research Profile

Disorders

Chemicals & Drugs

Procedures

Physiology

Postmenopause

Concepts & Ideas

Co-author Network

Publications

TOP 3
Paul E Goss; James N Ingle; David B Johnson; Istvan Lang; Pedro E R Liedke; Edith A Perez; Kathleen I Pritchard; Manuela Rabaglio; Rafat H Ansari; G Thomas Budd; Haji Chalchal; Judy-Anne W Chapman; David P D'Souza; Catherine Elliott; Matthew J Ellis; Karen Gelmon; George W Sledge; Silvana Spadafora; Vered Stearns; Richard Tozer; Lois E Shepherd
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Mohan Liu; Yusuke Nakamura; Donald W Northfelt; Edith A Perez; Tracy L Pietrzak; Mark Robson; Daniel J Schaid; Liewei Wang; Anthony Batzler; Aman U Buzdar; Erin E Carlson; Brooke L Fridley; Matthew P Goetz; James N Ingle; Gregory D Jenkins; Michiaki Kubo; Clark V Williard; Richard M Weinshilboum
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Daniel J Schaid; James N Ingle; Gregory D Jenkins; Richard M Weinshilboum
Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Ingle (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paul E Goss; James N Ingle; David B Johnson; Istvan Lang; Pedro E R Liedke; Edith A Perez; Kathleen I Pritchard; Manuela Rabaglio; Rafat H Ansari; G Thomas Budd; Haji Chalchal; Judy-Anne W Chapman; David P D'Souza; Catherine Elliott; Matthew J Ellis; Karen Gelmon; George W Sledge; Silvana Spadafora; Vered Stearns; Richard Tozer; Lois E Shepherd
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(11):1398-404.
2013: Mohan Liu; Yusuke Nakamura; Donald W Northfelt; Edith A Perez; Tracy L Pietrzak; Mark Robson; Daniel J Schaid; Liewei Wang; Anthony Batzler; Aman U Buzdar; Erin E Carlson; Brooke L Fridley; Matthew P Goetz; James N Ingle; Gregory D Jenkins; Michiaki Kubo; Clark V Williard; Richard M Weinshilboum
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Molecular endocrinology (Baltimore, Md.) 2013;27(4):657-70.
2013: Daniel J Schaid; James N Ingle; Gregory D Jenkins; Richard M Weinshilboum
Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies.
Genetic epidemiology 2013;37(3):229-38.
2013: Paul E Goss; James N Ingle; Robert B Livingston; Silvana Martino; Hyman Muss; Edith A Perez; Kathleen I Pritchard; Nicholas J Robert; Lois E Shepherd; David A Cameron; Y Chavarri-Guerra; Nancy E Davidson; T Whelan; Dongsheng Tu
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(2):355-61.
2013: John Hawse; James N Ingle; Wilma L Lingle; Kevin S Pitel; Mine S Cicek; Anne Gingery; Matthew P Goetz; Sarah B Grygo; Malayannan Subramaniam; Zhifu Sun; Xianglin Wu; Thomas C Spelsberg
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
PloS one 2013;8(1):e54613.
2012: Sandhya Pruthi; Cheryl L Beseler; Ercole L Cavalieri; James N Ingle; Nicole P Sandhu; Vera J Suman; Li Yang; Eleanor G Rogan
Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk.
The Journal of steroid biochemistry and molecular biology 2012;132(1-2):73-9.
2012: Ianko D Iankov; James N Ingle; Rae M Myers; Kah-Whye Peng; Stephen J Russell; Cory Allen; Mark J Federspiel; Evanthia C Galanis
Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(6):1139-47.
2012: Mohan Liu; Svetomir N Markovic; Taisei Mushiroda; Yusuke Nakamura; Daniel J Schaid; Liewei Wang; Tim Bongartz; Paul E Goss; John Hawse; James N Ingle; Naoyuki Kamatani; Michiaki Kubo; Richard M Weinshilboum
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Breast cancer research : BCR 2012;14(2):R41.
2012: Daniel J Schaid; Jason P Sinnwell; D Lawrence Wickerham; Joseph P Costantino; Paul E Goss; James N Ingle; Gregory D Jenkins; Michiaki Kubo; Shannon K McDonnell; Richard M Weinshilboum
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Genetic epidemiology 2012;36(1):3-16.
2011: Edith A Perez; Thomas M Pisansky; Vera J Suman; Daniel W Visscher; Joanne Zujewski; Beiyun Chen; Shaker R Dakhil; Nancy E Davidson; Julie R Gralow; James N Ingle; Peter A Kaufman; Alvaro Moreno-Aspitia; Robert B Jenkins
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(34):4491-7.
2011: Ann M Moyer; Stephanie L Safgren; Vera J Suman; Richard M Weinshilboum; Matthew M Ames; Rajeswari Avula; John L Black; James N Ingle; Mary J Kuffel; Matthew P Goetz
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Pharmacogenomics 2011;12(11):1535-43.
2011: Michael K Asiedu; Marshall D Behrens; James N Ingle; Derek Radisky; Keith L Knutson
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.
Cancer research 2011;71(13):4707-19.
2011: James N Ingle
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Steroids 2011;76(8):765-7.
2011: Paul E Goss; James N Ingle; Karen C Johnson; Lisa W Martin; Elizabeth Maunsell; Anne McTiernan; Pascal Pujol; Harriet Richardson; John Robbins; Gloria E Sarto; Dongsheng Tu; Jean Wactawski-Wende; Eric Winquist; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Carol J Fabian; Patricia Farmer; Judy E Garber; Karen A Gelmon
Exemestane for breast-cancer prevention in postmenopausal women.
The New England journal of medicine 2011;364(25):2381-91.
2011: Xianglin Wu; Matthew P Goetz; Sarah B Grygo; James N Ingle; Wilma L Lingle; Vivian C Negron; Thomas C Spelsberg; Malayannan Subramaniam; Zhifu Sun; John Hawse
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Breast cancer research : BCR 2011;13(2):R27.
2011: Celine M Vachon; Hironobu Sasano; Karthik Ghosh; Kathleen R Brandt; David A Watson; Carol Reynolds; Wilma L Lingle; Paul E Goss; Rong Li; Sarah E Aiyar; Christopher G Scott; V Shane Pankratz; Richard J Santen; James N Ingle
Aromatase immunoreactivity is increased in mammographically dense regions of the breast.
Breast cancer research and treatment 2011;125(1):243-52.
2010: James N Ingle; Daniel J Schaid; Paul E Goss; Mohan Liu; Taisei Mushiroda; Judy-Anne W Chapman; Michiaki Kubo; Gregory D Jenkins; Anthony Batzler; Lois Shepherd; Joseph Pater; Liewei Wang; Matthew J Ellis; Vered Stearns; Daniel C Rohrer; Matthew P Goetz; Kathleen I Pritchard; David A Flockhart; Yusuke Nakamura; Richard M Weinshilboum
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4674-82.
2010: Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):4307-15.
2010: Ianko D Iankov; Pavlos Msaouel; Cory Allen; Mark J Federspiel; Peggy A Bulur; Allan B Dietz; Dennis A Gastineau; Yasuhiro Ikeda; James N Ingle; stephen russell; Evanthia C Galanis
Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
Breast cancer research and treatment 2010;122(3):745-54.
2010: Monica M Reinholz; Shawn P Zinnen; Amylou Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
Bone 2010;47(1):12-22.
2010: James N Ingle; Aman U Buzdar; Daniel J Schaid; Matthew P Goetz; Anthony Batzler; Mark Robson; Donald W Northfelt; Janet E Olson; Edith A Perez; Zeruesenay Desta; Randy A Weintraub; Clark V Williard; David A Flockhart; Richard M Weinshilboum
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Cancer research 2010;70(8):3278-86.
2010: James N Ingle
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Breast cancer research : BCR 2010;12 Suppl 4():S17.
2010: James N Ingle; William R Miller
Introduction to session on undue and disproportionate influences.
Breast cancer research : BCR 2010;12 Suppl 4():S12.
2010: Malayannan Subramaniam; John Hawse; Nalini M Rajamannan; James N Ingle; Thomas C Spelsberg
Functional role of KLF10 in multiple disease processes.
BioFactors (Oxford, England) 2010;36(1):8-18.
2010: Liewei Wang; Katarzyna A Ellsworth; Irene Moon; Linda L Pelleymounter; Bruce W Eckloff; Yvette N Martin; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Vera J Suman; Saranya Ravi; J Michael Dixon; William R Miller; Eric D Wieben; Aman Buzdar; Richard M Weinshilboum; James N Ingle
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Cancer research 2010;70(1):319-28.
2010: Sejal S Shah; Rhett P Ketterling; Matthew P Goetz; James N Ingle; Carol A Reynolds; Edith A Perez; Beiyun Chen
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Human pathology 2010;41(1):103-6.
2010: Lavakumar Karyampudi; Christopher J Krco; Kimberly R Kalli; Courtney L Erskine; Lynn C Hartmann; Karin Goodman; James N Ingle; Matthew J Maurer; Aziza Nassar; Chao Yu; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.
Cancer immunology, immunotherapy : CII 2010;59(1):161-71.
2009: Rajini Katipamula; Amy C Degnim; Tanya L Hoskin; Judy C Boughey; Charles L Loprinzi; Clive S Grant; Kathleen R Brandt; Sandhya Pruthi; Christopher G Chute; Janet E Olson; Fergus J. Couch; James N Ingle; Matthew P Goetz
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4082-8.
2009: Clive S Grant; James N Ingle; Vera J Suman; Daniel A Dumesic; D Lawrence Wickerham; Richard D Gelber; Patrick J Flynn; Lorna M Weir; Mattia Intra; Wayne O Jones; Edith A Perez; Lynn C Hartmann
Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3620-6.
2009: Marta Santisteban; Jennifer M Reiman; Michael K Asiedu; Marshall D Behrens; Aziza Nassar; Kimberly R Kalli; Paul Haluska; James N Ingle; Lynn C Hartmann; Masoud H Manjili; Derek Radisky; Soldano Ferrone; Keith L Knutson
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
Cancer research 2009;69(7):2887-95.
2009: Xianglin Wu; John Hawse; Malayannan Subramaniam; Matthew P Goetz; James N Ingle; Thomas C Spelsberg
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Cancer research 2009;69(5):1722-7.
2009: Matthew P Goetz; Matthew M Ames; M Weinshilboum; James N Ingle
Endocrine therapy in 2009: consideration of the tumor and the host.
Oncology (Williston Park, N.Y.) 2009;23(2):150-1, 154.
2008: Sook Shin; Denis G Bosc; James N Ingle; Thomas C Spelsberg; Ralf Janknecht
Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors.
Journal of cellular biochemistry 2008;105(3):866-74.
2008: Paul E Goss; Hyman Muss; James N Ingle; Timothy J Whelan; Melinda Wu
Extended adjuvant endocrine therapy in breast cancer: current status and future directions.
Clinical breast cancer 2008;8(5):411-7.
2008: Matthew P Goetz; Vera J Suman; Fergus J. Couch; Matthew M Ames; James M Rae; Mark G Erlander; Xiao-Jun Ma; Dennis C Sgroi; Carol A Reynolds; Wilma L Lingle; Richard M Weinshilboum; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5864-8.
2008: Yuan Ji; Janet Olson; Jianping Zhang; Michelle A T Hildebrandt; Liewei Wang; James N Ingle; Zachary S Fredericksen; Thomas A Sellers; William Miller; J Michael Dixon; Hiltrud Brauch; Michel Eichelbaum; Christina Justenhoven; Ute Hamann; Yon Ko; Thomas Brüning; Jenny Chang-Claude; Shan Wang-Gohrke; Daniel J Schaid; Richard M Weinshilboum
Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.
Cancer research 2008;68(14):5997-6005.
2008: John Hawse; Malayannan Subramaniam; David G Monroe; Amanda H Hemmingsen; James N Ingle; Sundeep Khosla; Merry Jo Oursler; Thomas C Spelsberg
Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain.
Molecular endocrinology (Baltimore, Md.) 2008;22(7):1579-95.
2008: James N Ingle; Dongsheng Tu; Joseph L Pater; Hyman Muss; Silvana Martino; Nicholas J Robert; Martine J Piccart; M Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
2008: Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
2008: Judith A Gilbert; Matthew P Goetz; Carol A Reynolds; James N Ingle; Karin F Giordano; Vera J Suman; Hilary E Blair; Robert B Jenkins; Wilma L Lingle; Monica M Reinholz; Alex A. Adjei; Matthew M Ames
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Molecular cancer therapeutics 2008;7(4):944-51.
2008: Edith A Perez; Vera J Suman; Nancy E Davidson; George W Sledge; Peter A Kaufman; Clifford Hudis; Silvana Martino; Julie R Gralow; Shaker R Dakhil; James N Ingle; Eric P Winer; Karen Gelmon; Bernard J Gersh; Allan S Jaffe; Richard J Rodeheffer
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1231-8.
2008: James N Ingle
Pharmacogenomics of tamoxifen and aromatase inhibitors.
Cancer 2008;112(3 Suppl):695-9.
2008: John Hawse; Malayannan Subramaniam; James N Ingle; Merry Jo Oursler; Nalini M Rajamannan; Thomas C Spelsberg
Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors.
Journal of cellular biochemistry 2008;103(2):383-92.
2008: James N Ingle
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.
Breast cancer research : BCR 2008;10 Suppl 4():S17.
2007: Paul E Goss; Harriet Richardson; Rowan T Chlebowski; Dianne Johnston; Gloria E Sarto; Elizabeth Maunsell; James N Ingle; José E Alés-Martinez
National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
Clinical breast cancer 2007;7(11):895-900.
2007: Sandhya Pruthi; Judy C Boughey; Kathleen R Brandt; Amy C Degnim; Grace K Dy; Matthew P Goetz; Edith A Perez; Carol A Reynolds; Paula J Schomberg; James N Ingle
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
Mayo Clinic proceedings. Mayo Clinic 2007;82(9):1131-40.
2007: Sandhya Pruthi; Kathleen R Brandt; Amy C Degnim; Matthew P Goetz; Edith A Perez; Carol A Reynolds; Paula J Schomberg; Grace K Dy; James N Ingle
A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis.
Mayo Clinic proceedings. Mayo Clinic 2007;82(8):999-1012.
2007: Svetomir N Markovic; Vera J Suman; Ravi A Rao; James N Ingle; Judith S Kaur; Lori A Erickson; Henry C Pitot; Gary A Croghan; Robert R McWilliams; Jaime Merchan; Lisa A Kottschade; Wendy K Nevala; Cindy B Uhl; Jacob Allred; Edward T. Creagan
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.
American journal of clinical oncology 2007;30(3):303-9.
2007: Celine M Vachon; James N Ingle; V J Suman; Christopher G Scott; H Gottardt; Janet E Olson; P E Goss
Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
Breast (Edinburgh, Scotland) 2007;16(2):204-10.
2007: Janet E Olson; James N Ingle; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Yanhong Wu; Fergus J. Couch; Celine M Vachon; Thomas A Sellers; Richard M Weinshilboum
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
Breast cancer research and treatment 2007;102(2):237-47.
2007: Janet E Olson; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; James N Ingle; Yanhong Wu; Fergus J. Couch; Thomas A Sellers; Richard M Weinshilboum; Celine M Vachon
A comprehensive examination of CYP19 variation and breast density.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(3):623-5.
2007: Matthew P Goetz; James N Ingle; Fergus J. Couch
Gene-expression-based predictors for breast cancer.
The New England journal of medicine 2007;356(7):752; author reply 752-3.
2007: Matthew P Goetz; Stacey K Knox; Vera J Suman; James M Rae; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J. Couch; Wilma L Lingle; Richard M Weinshilboum; Emily G Barr Fritcher; Andrea M Nibbe; Zeruesenay Desta; Anne Nguyen; David A Flockhart; Edith A Perez; James N Ingle
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Breast cancer research and treatment 2007;101(1):113-21.
2006: Yvette N Martin; Janet E Olson; James N Ingle; Robert A Vierkant; Zachary S Fredericksen; V Shane Pankratz; Yanhong Wu; Daniel J Schaid; Thomas A Sellers; Richard M Weinshilboum
Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(11):2322-4.
2006: Svetomir N Markovic; Vera J Suman; James N Ingle; Judith S Kaur; Henry C Pitot; Charles L Loprinzi; Ravi D Rao; Edward T. Creagan; Mark Pittelkow; Jakob B Allred; Wendy K Nevala; Esteban Celis
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
American journal of clinical oncology 2006;29(4):352-60.
2006: Edith A Perez; Vera J Suman; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Wilma L Lingle; Patrick J Flynn; James N Ingle; Daniel W Visscher; Robert B Jenkins
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3032-8.
2006: James N Ingle; Vera J Suman; James A Mailliard; John W Kugler; James E Krook; John C Michalak; Thomas M Pisansky; Lester E Wold; John H Donohue; Matthew P Goetz; Edith A Perez
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Breast cancer research and treatment 2006;98(2):217-22.
2006: Matthew P Goetz; Vera J Suman; James N Ingle; Andrea M Nibbe; Daniel W Visscher; Carol A Reynolds; Wilma L Lingle; Mark G Erlander; Xiao-Jun Ma; Dennis C Sgroi; Edith A Perez; Fergus J. Couch
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2080-7.
2006: James N Ingle; Vera J Suman; Kendrith M Rowland; Deepu Mirchandani; Albert M Bernath; John K Camoriano; Paul A. Fishkin; Daniel A Nikcevich; Edith A Perez
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1052-6.
2006: Cynthia X Ma; P Steen; Kendrith M Rowland; R D Niedringhaus; Tom R Fitch; John W Kugler; David W Hillman; Edith A Perez; James N Ingle; Alex A. Adjei
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):226-31.
2006: Ravi D Rao; Shernan G Holtan; James N Ingle; Gary A Croghan; Lisa A Kottschade; Edward T. Creagan; Judith S Kaur; Henry C Pitot; Svetomir N Markovic
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.
Cancer 2006;106(2):375-82.
2006: Svetomir N Markovic; Allan B Dietz; Carl W Greiner; Mary L Maas; Greg W Butler; Douglas J Padley; Peggy A Bulur; Jacob B Allred; Edward T. Creagan; James N Ingle; Dennis A Gastineau; Stanimir Vuk-Pavlovic
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.
Journal of translational medicine 2006;4():35.
2005: Matthew P Goetz; James M Rae; Vera J Suman; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J. Couch; Wilma L Lingle; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9312-8.
2005: Edith A Perez; Vera J Suman; Kendrith M Rowland; James N Ingle; Muhammad Salim; Charles L Loprinzi; Patrick J Flynn; James A Mailliard; Carl G Kardinal; James E Krook; Abby R Thrower; Daniel W Visscher; Robert B Jenkins
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Clinical breast cancer 2005;6(5):425-32.
2005: Edward Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
The New England journal of medicine 2005;353(16):1673-84.
2005: Monica M Reinholz; Andrea M Nibbe; Leslie M Jonart; Kathleen Kitzmann; Vera J Suman; James N Ingle; Raymond L Houghton; Barbara K Zehentner; Patrick C Roche; Wilma L Lingle
Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3722-32.
2005: Jacqueline M Lafky; Andre T Baron; Elsa M Cora; David W Hillman; Vera J Suman; Edith A Perez; James N Ingle; Nita Maihle
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Cancer research 2005;65(8):3059-62.
2005: Patrick A Burch; James A Mailliard; David W Hillman; Edith A Perez; James E Krook; Kendrith M Rowland; Michael H Veeder; Michael W Cannon; James N Ingle
Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.
American journal of clinical oncology 2005;28(2):195-200.
2005: James M Rae; Matthew P Goetz; Daniel F Hayes; James N Ingle; Lang Li; Anna Maria Storniolo; Vered Stearns; David A Flockhart
CYP2D6 genotype and tamoxifen response.
Breast cancer research : BCR 2005;7(5):E6.
2005: Edith A Perez; Vera J Suman; Tom R Fitch; James A Mailliard; James N Ingle; John T Cole; Michael H Veeder; Patrick J Flynn; Daniel J Walsh; Ferdinand K Addo
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Oncology 2005;69(2):117-21.
2004: Edith A Perez; Vera J Suman; Nancy E Davidson; Peter A Kaufman; Silvana Martino; Shaker R Dakhil; James N Ingle; Richard J Rodeheffer; Bernard J Gersh; Allan S Jaffe
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3700-4.
2004: Edith A Perez; David W Hillman; James A Mailliard; James N Ingle; J Michael Ryan; Tom R Fitch; Kendrith M Rowland; Carl G Kardinal; James E Krook; John W Kugler; Shaker R Dakhil
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(14):2849-55.
2004: Monica M Reinholz; Ming-Wen An; Steven A Johnsen; Malayannan Subramaniam; Vera J Suman; James N Ingle; Patrick C Roche; Thomas C Spelsberg
Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue.
Breast cancer research and treatment 2004;86(1):75-88.
2004: Dylan V Miller; Alexey A Leontovich; Wilma L Lingle; Vera J Suman; Maureen L Mertens; James Lillie; Kimberly A Ingalls; Edith A Perez; James N Ingle; Fergus J. Couch; Daniel W Visscher
Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2004;17(7):756-64.
2002: Edith A Perez; L Geeraerts; Vera J Suman; Alex A. Adjei; Andre T Baron; Alan K Hatfield; Nita Maihle; John C Michalak; Steven A Kuross; John W Kugler; Jacqueline M Lafky; James N Ingle
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1225-35.
2002: Colleen S Sinclair; Camilo Adem; Ali Naderi; Cheryl L Soderberg; Michele Johnson; Kangjian Wu; Linda Wadum; Vicki L Couch; Thomas A Sellers; Daniel J Schaid; Jeffrey Slezak; Zachary S Fredericksen; James N Ingle; Lynn Hartmann; Robert B Jenkins; Fergus J. Couch
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
Cancer research 2002;62(13):3587-91.
2002: Patrick C Roche; Vera J Suman; Robert B Jenkins; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Ferdinand K Addo; Bronagh Murphy; James N Ingle; Edith A Perez
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
Journal of the National Cancer Institute 2002;94(11):855-7.
2002: Monica M Reinholz; Stephen J Iturria; James N Ingle; Patrick C Roche
Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.
Breast cancer research and treatment 2002;74(3):255-69.
2002: Thomas E Witzig; Blaise Bossy; Teresa Kimlinger; Patrick C Roche; James N Ingle; Clive Grant; John Donohue; Vera J Suman; Douglas Harrington; Jose Torre-Bueno; Kenneth D Bauer
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1085-91.
2002: Edith A Perez; Patrick C Roche; Robert B Jenkins; Carol A Reynolds; Kevin C Halling; James N Ingle; Lester E Wold
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
Mayo Clinic proceedings. Mayo Clinic 2002;77(2):148-54.
2001: Guojun Wu ; Colleen S Sinclair; Shannon R Hinson; James N Ingle; Patrick C Roche; Fergus J. Couch
Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors.
Cancer research 2001;61(13):4951-5.
2000: Guojun Wu ; Colleen S Sinclair; J Paape; James N Ingle; Patrick C Roche; C David James; Fergus J. Couch
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.
Cancer research 2000;60(19):5371-5.
2000: Edith A Perez; David W Hillman; Philip J Stella; James E Krook; Lynn C Hartmann; Tom R Fitch; Alan K Hatfield; James A Mailliard; Suresh Nair; Carl G Kardinal; James N Ingle
A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.
Cancer 2000;88(1):124-31.
1999: James N Ingle; Vera J Suman; Patricia A. Johnson; J E Krook; James A Mailliard; R H Wheeler; C L Loprinzi; Edith A Perez; V C Jordan; M Dowsett
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1642-9.
1999: James N Ingle; V J Suman; V C Jordan; M Dowsett
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Endocrine-related cancer 1999;6(2):265-9.
1999: Daniel Rayson; Alex A. Adjei; Vera J Suman; L E Wold; James N Ingle
Metaplastic breast cancer: prognosis and response to systemic therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):413-9.
1999: James N Ingle; Vera J Suman; Carl G Kardinal; James E Krook; James A Mailliard; Michael H Veeder; Charles L Loprinzi; Robert J Dalton; Lynn C Hartmann; C A Conover; M N Pollak
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
Cancer 1999;85(6):1284-92.
1999: Prema P Peethambaram; James N Ingle; Vera J Suman; Lynn C Hartmann; Charles L Loprinzi
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.
Breast cancer research and treatment 1999;54(2):117-22.
1998: Daniel Rayson; Charles Erlichman; Vera J Suman; Patrick C Roche; L E Wold; James N Ingle; J H Donohue
Molecular markers in male breast carcinoma.
Cancer 1998;83(9):1947-55.
1997: James N Ingle; Patricia A. Johnson; Vera J Suman; JB Gerstner; James A Mailliard; John K Camoriano; Dean H Gesme; Charles L Loprinzi; Alan K Hatfield; Lynn C Hartmann
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.
Cancer 1997;80(2):218-24.
1997: James N Ingle; Carl G Kardinal; Vera J Suman; Michael H Veeder; Paul L Schaefer; RJ Kirschling; James A Mailliard
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Breast cancer research and treatment 1997;43(3):193-200.
1997: James N Ingle; D I Twito; Vera J Suman; James E Krook; J A Maillard; Harold E Windschitl; RF Marschke
Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer.
American journal of clinical oncology 1997;20(1):69-72.
1996: S R Alberts; James N Ingle; P R Roche; S S Cha; L E Wold; Gist Henry Farr; James E Krook; H S Wieand
Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials.
Cancer 1996;78(4):764-72.
1996: Thomas M Pisansky; Charles L Loprinzi; S S Cha; R J Fitzgibbons; Clive S Grant; A C Hass; N F Reuter; L E Wold; James N Ingle; Carl G Kardinal
A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma.
Cancer 1996;77(12):2520-8.
1996: M V Dhodapkar; James N Ingle; S S Cha; James A Mailliard; H S Wieand
Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
Cancer 1996;77(4):683-90.
1996: James N Ingle; Carl G Kardinal; Vera J Suman; James E Krook; A K Hatfield
Octreotide as first-line treatment for women with metastatic breast cancer.
Investigational new drugs 1996;14(2):235-7.
1995: James N Ingle; James E Krook; James A Mailliard; Lynn C Hartmann; H S Wieand
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
American journal of clinical oncology 1995;18(6):498-501.
1995: L E Wold; James N Ingle; Thomas M Pisansky; R E Johnson; J H Donohue
Prognostic factors for patients with carcinoma of the breast.
Mayo Clinic proceedings. Mayo Clinic 1995;70(7):678-9.
1995: M V Dhodapkar; James N Ingle; D L Ahmann
Estrogen replacement therapy withdrawal and regression of metastatic breast cancer.
Cancer 1995;75(1):43-6.
1994: J M Cunningham; James N Ingle; S H Jung; S S Cha; L E Wold; G Farr; T E Witzig; James E Krook; H S Wieand; J S Kovach
p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis.
Journal of the National Cancer Institute 1994;86(24):1871-3.
1994: Lynn C Hartmann; James N Ingle; L E Wold; Gist Henry Farr; J P Grill; J Q Su; Nita Maihle; James E Krook; Thomas E Witzig; Patrick C Roche
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.
Cancer 1994;74(11):2956-63.
1994: Thomas E Witzig; James N Ingle; S S Cha; Daniel J Schaid; R L Tabery; L E Wold; C Grant; N J Gonchoroff; J A Katzmann
DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer.
Cancer 1994;74(6):1752-61.
1994: Thomas M Pisansky; M Y Halyard; A L Weaver; J H Donohue; G L Grado; Clive S Grant; L C Hartmann; James N Ingle; Paula J Schomberg; L E Wold
Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience.
Mayo Clinic proceedings. Mayo Clinic 1994;69(6):515-24.
1994: James N Ingle; J F Foley; James A Mailliard; James E Krook; Lynn C Hartmann; S H Jung; Michael H Veeder; Dean H Gesme; Alan K Hatfield; Richard M Goldberg
Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Cancer 1994;73(9):2337-43.
1993: Thomas M Pisansky; James N Ingle; Daniel J Schaid; A C Hass; James E Krook; J H Donohue; T E Witzig; L E Wold
Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors.
Cancer 1993;72(4):1247-60.
1993: Charles L Loprinzi; J Duffy; James N Ingle
Postchemotherapy rheumatism.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):768-70.
1993: Thomas E Witzig; James N Ingle; Daniel J Schaid; L E Wold; J F Barlow; N J Gonchoroff; JB Gerstner; James E Krook; C S Grant; J A Katzmann
DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(2):351-9.
1991: Thomas E Witzig; N J Gonchoroff; Terry M Therneau; D T Gilbertson; L E Wold; C Grant; J Grande; J A Katzmann; D L Ahmann; James N Ingle
DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication.
Cancer 1991;68(8):1781-8.
1991: James N Ingle; James A Mailliard; Daniel J Schaid; James E Krook; Dean H Gesme; Harold E Windschitl; D M Pfeifle; P S Etzell; J G Gerstner; H J Long
A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
Cancer 1991;68(1):34-9.
1991: D L Ahmann; Daniel J Schaid; James N Ingle; H F Bisel; A J Schutt; Jan C Buckner; H J Long; J Rubin
A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.
American journal of clinical oncology 1991;14(3):179-83.
1991: James N Ingle; D I Twito; Daniel J Schaid; S A Cullinan; James E Krook; James A Mailliard; Loren K Tschetter; H J Long; J G Gerstner; Harold E Windschitl
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
Cancer 1991;67(4):886-91.
1991: Charles L Loprinzi; James N Ingle; Daniel J Schaid; Jan C Buckner; J H Edmonson; C J Allegra
5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study.
American journal of clinical oncology 1991;14(1):30-2.
1990: John K Camoriano; Charles L Loprinzi; James N Ingle; Terry M Therneau; James E Krook; Michael H Veeder
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(8):1327-34.
1990: James N Ingle; James E Krook; Daniel J Schaid; L K Everson; James A Mailliard; H J Long; G W McCormack
Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure.
American journal of clinical oncology 1990;13(2):93-7.
1989: James N Ingle; James A Mailliard; Daniel J Schaid; James E Krook; JB Gerstner; D M Pfeifle; RF Marschke; H J Long; G W McCormack; J F Foley
Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer.
American journal of clinical oncology 1989;12(6):474-80.
1989: James N Ingle
Principles of therapy in advanced breast cancer.
Hematology/oncology clinics of North America 1989;3(4):743-63.
1989: Jan C Buckner; J H Edmonson; James N Ingle; Daniel J Schaid
Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
American journal of clinical oncology 1989;12(5):384-6.
1989: RF Marschke; James N Ingle; Daniel J Schaid; James E Krook; James A Mailliard; S A Cullinan; D M Pfeifle; Henry Votava; Larry P Ebbert; Harold E Windschitl
Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
Cancer 1989;63(10):1931-7.
1989: Edward T. Creagan; James N Ingle; A J Schutt; Daniel J Schaid
A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma.
American journal of clinical oncology 1989;12(2):152-5.
1989: James N Ingle; L K Everson; H S Wieand; S A Cullinan; L E Wold; J B Hagen; J K Martin; James E Krook; R G Fitzgibbons; J F Foley
Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Cancer 1989;63(7):1257-64.
1989: Jan C Buckner; James N Ingle; L K Everson; Judith R O'Fallon; S A Cullinan; D L Ahmann; James E Krook; D M Pfeifle
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer.
Breast cancer research and treatment 1989;13(2):135-42.
1988: H J Long; Daniel J Schaid; A J Schutt; James N Ingle; Charles L Loprinzi; J H Edmonson
Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
American journal of clinical oncology 1988;11(5):524-7.
1988: James N Ingle; L K Everson; H S Wieand; J K Martin; Henry Votava; L E Wold; James E Krook; S A Cullinan; J K Paulsen; D I Twito
Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(9):1388-96.
1988: James N Ingle; D I Twito; Daniel J Schaid; S A Cullinan; James E Krook; James A Mailliard; RF Marschke; H J Long; J G Gerstner; Harold E Windschitl
Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(5):825-31.
1988: Charles L Loprinzi; James N Ingle; Daniel J Schaid; Jan C Buckner; J H Edmonson
Progress report on a phase II trial of 5-fluorouracil plus citrovorum factor in women with metastatic breast cancer.
Advances in experimental medicine and biology 1988;244():255-9.
1987: D L Ahmann; Daniel J Schaid; H F Bisel; Richard G Hahn; J H Edmonson; James N Ingle
The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1928-32.
1986: James N Ingle; H J Long; A J Schutt; M N Chang
Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer.
American journal of clinical oncology 1986;9(5):379-81.
1986: James N Ingle; S J Green; D L Ahmann; H J Long; J H Edmonson; J Rubin; M N Chang; Edward T. Creagan
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(6):958-64.
1986: James N Ingle; James E Krook; S J Green; T P Kubista; L K Everson; D L Ahmann; M N Chang; H F Bisel; Harold E Windschitl; D I Twito
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(2):178-85.
1985: James N Ingle; D M Pfeifle; S J Green; L K Kvols; S F Brunk; N F Reuter; James E Krook; J A Laurie; L K Everson; RF Marschke
Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure.
American journal of clinical oncology 1985;8(4):275-82.
1985: James E Krook; James N Ingle; S J Green; W D Bowman; L K Everson; Harold E Windschitl; RF Marschke; J A Laurie; S A Cullinan; D M Pfeifle
Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
Cancer treatment reports 1985;69(4):355-61.
1983: James N Ingle; S F Brunk; James E Krook; L K Everson; S J Green; L K Kvols; P S Etzell
Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure.
Cancer treatment reports 1983;67(10):955-6.
1982: D L Ahmann; Judith R O'Fallon; P W Scanlon; W S Payne; H F Bisel; J H Edmonson; S Frytak; Richard G Hahn; James N Ingle; J Rubin; Edward T. Creagan
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.
American journal of clinical oncology 1982;5(4):371-81.
1982: D L Ahmann; S J Green; H F Bisel; James N Ingle; Richard G Hahn; R A Lee; J H Edmonson
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
American journal of clinical oncology 1982;5(4):355-8.
1982: James N Ingle; S J Green; D L Ahmann; J H Edmonson; W C Nichols; S Frytak; J Rubin
Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Cancer research 1982;42(8 Suppl):3461s-3467s.
1981: James N Ingle; D L Ahmann; S J Green; J H Edmonson; H F Bisel; L K Kvols; W C Nichols; Edward T. Creagan; Richard G Hahn; J Rubin; S Frytak
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
The New England journal of medicine 1981;304(1):16-21.